Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation.

Silbermann, Rebecca W; Schmidt, Timothy Martin; Bal, Susan; Dhakal, Binod; Dholaria, Bhagirathbhai; Biltibo, Eden; Chhabra, Saurabh; Giri, Smith; Godby, Kelly N; Gowda, Sonia; Medvedova, Eva; Cornell, Robert F; Callander, Natalie S; Costa, Luciano J

Silbermann, Rebecca W; Schmidt, Timothy Martin; Bal, Susan; Dhakal, Binod; Dholaria, Bhagirathbhai; Biltibo, Eden; Chhabra, Saurabh; Giri, Smith; Godby, Kelly N; Gowda, Sonia; Medvedova, Eva; Cornell, Robert F; Callander, Natalie S; Costa, Luciano J.

Affiliation

Silbermann RW; Knight Cancer Institute Oregon Health and Science University Portland Oregon USA.
Schmidt TM; Carbone Cancer Center University of Wisconsin Madison Wisconsin USA.
Bal S; University of Alabama at Birmingham Birmingham AL UK.
Dhakal B; Division of Hematology/Oncology, Department of Medicine Medical College of Wisconsin Milwaukee Wisconsin USA.
Dholaria B; Vanderbilt University Medical Center Nashville TN USA.
Biltibo E; Vanderbilt University Medical Center Nashville TN USA.
Chhabra S; Division of Hematology/Oncology, Department of Medicine Medical College of Wisconsin Milwaukee Wisconsin USA.
Giri S; Institute for Cancer Outcomes and Survivorship University of Alabama at Birmingham Birmingham AL UK.
Godby KN; University of Alabama at Birmingham Birmingham AL UK.
Gowda S; Department of Internal Medicine Oregon Health and Science University Portland Oregon USA.
Medvedova E; Knight Cancer Institute Oregon Health and Science University Portland Oregon USA.
Cornell RF; Vanderbilt University Medical Center Nashville TN USA.
Callander NS; Carbone Cancer Center University of Wisconsin Madison Wisconsin USA.
Costa LJ; University of Alabama at Birmingham Birmingham AL UK.